|Provectus Biopharmaceuticals, Inc.|
7327 Oak Ridge Highway
United States - Map
Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its product line includes PV-10, which has completed Phase II study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. The company is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, the company is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products. Additionally, it develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of various skin cancers. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
|Dr. H. Craig Dees Ph.D.,
Chairman, Chief Exec. Officer, Chief Exec. Officer of Xantech and Director of Xantech
|Dr. Timothy C. Scott Ph.D.,
Pres, Director, Pres of Xantech and Director of Xantech
|Mr. Peter R. Culpepper CPA, MBA,
Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Corp. Treasurer and Sec.
|Dr. Eric A. Wachter Ph.D.,
Chief Technology Officer and Exec. VP
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|